Q-omics provides the consensus-scored ENGASE profile across patient tissues and cancer cell-line models. ENGASE expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ENGASE is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ENGASE protein abundance shows 19,561 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where ENGASE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENGASE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENGASE survival associations across molecular data types. ENGASE RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENGASE RNA expression–survival associations across cancer types. High ENGASE expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in BLCA, PAAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ENGASE RNA expression.
This table summarizes ENGASE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ENGASE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENGASE shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and KIRP. The HNSC box plot shows higher ENGASE RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with ENGASE in patient tissues and cancer cell lines. In patient samples, ENGASE shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ENGASE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
